Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lumbar Fusion With The Icotec CF/PEEK Pedicle System In Combination With The Icotec CF/PEEK TLIF Cage ETurn™

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02087267
Recruitment Status : Recruiting
First Posted : March 14, 2014
Last Update Posted : May 1, 2019
Sponsor:
Information provided by (Responsible Party):
Sitona AG

Brief Summary:
The objective of the PMCF is to collect outcome information on patients suffering from symptomatic degenerative disc disease or degenerative spondylolisthesis requiring 1- or 2-level lumbar or lumbar-sacral spinal fusion with posterior instrumentation and therefore receiving the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™.

Condition or disease Intervention/treatment
Degeneration of Lumbar Intervertebral Disc Degenerative Spondylolisthesis Procedure: 1- or 2-level spinal fusion

Detailed Description:

Background: At present, metal pedicle screw systems made from titanium or stainless steel are commonly used for posterior stabilization. One disadvantage of theses metal devices is that they cause shadows and artifacts on CTs and MRIs which may hamper the postoperative exploration of the onset of spinal diseases and in particular the evaluation of the neuroforamina, the spinal canal and bone-implant interfaces. Therefore new concepts of pedicle screw devices use non-radiopaque materials such as carbon fiber-reinforced polyetheretherketone (CF/PEEK) without compromising mechanical properties compared to standard titanium implants and possibly reducing the risk for adjacent segment diseases.

Description of the study devices:

The icotec Pedicle System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of acute and chronic instabilities or deformities of the thoracic, lumbar and sacral spine. The carbon fiber-reinforced polyetheretherketone (CF/PEEK) that is used to produce the icotec pedicle system rod and screw shaft is a thermoplastic composite biomaterial exhibiting properties suitable for load-bearing orthopedic implants. The CF/PEEK material does not cause artifacts or shadows on adjacent tissues with all imaging modalities such as x-ray, CT, and MRI. Radiopaque markers or fibres made from titanium or tantalum are embedded. The pedicle system rod and screws allow this advantage to be realized without compromising mechanical properties compared to standard titanium implants.

Description of the study device - icotec CF/PEEK TLIF Cage ETurn: The icotec ETurn™ TLIF cage consists of a windowed body with a central slot, a distraction/ insertion wedge and surface treads on its cranial and caudal surfaces that serve to guide and anchor the implant (see figure 4). The concentrically arranged treads enable the implant to turn on its own from its position of insertion into the disc space to its transverse end position. The tread surfaces help to create a significantly larger pressure-bearing contact surface between the implant and the bone than the conventional pointed anchoring elements.

Risk Analysis and risk Management: Most of the risks of implant related, surgical and postoperative complications associated with the implantation of the icotec CF/PEEK Pedicle System in combination with the icotec ETurn™ TLIF cage, are comparable to the risks associated with other TLIF surgeries with cages and pedicle screw systems intended for lumbar spine stabilization.

risks and possible adverse outcomes have been identified for the icotec CF/PEEK Pedicle System as well as for the CF/PEEK TLIF Cage ETurn.

Legal Aspects: For this post-market investigation only CE-marked medical devices will be used within their intended purpose and no additional invasive or other stressful examinations are to be carried out.

All subjects will voluntarily sign the Informed Consent document. Ethics approval for the study will be obtained prior to starting the study

Data Monitoring: Independent on-site Monitoring will be performed at all investigational sites.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Lumbar Fusion With The Icotec CF/PEEK Pedicle System In Combination With The Icotec CF/PEEK TLIF Cage ETurn™
Study Start Date : March 2014
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
1- or 2-level spinal fusion
Patients suffering from symptomatic degenerative disc disease or degenerative spondylolisthesis grade 1 or 2 with chronic low back pain, pain in the leg or buttock, muscle weakness, sensation abnormalities and/or neurogenic claudication requiring 1- or 2-level lumbar or lumbar-sacral spinal fusion.
Procedure: 1- or 2-level spinal fusion
1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™




Primary Outcome Measures :
  1. Overall fusion rate [ Time Frame: 2 years postoperatively ]
    Outcome Measure by CT/MRI and clinical follow-up


Secondary Outcome Measures :
  1. Rate of pedicle system implant failures [ Time Frame: 2 years postoperatively ]
    Outcome Measure by CT/MRI and clinical follow-up

  2. Rate of implant related, surgery related, postoperative and general complications [ Time Frame: 2 years postoperatively ]
    Outcome Measure by CT/MRI and clinical follow-up

  3. Rate of subsequent surgical interventions [ Time Frame: 2 years postoperatively ]
    Outcome Measure by CT/MRI and clinical follow-up

  4. Change of the mean total Oswestry Low Back Pain Disability Questionnaire (ODI) [ Time Frame: Change from the preoperative baseline to the 2 year postoperative assessment ]
    clinical follow-up

  5. Change of the mean Visual Analogue Scale (VAS) on low back pain [ Time Frame: Change from the preoperative baseline to the 2 year postoperative assessment ]
    clinical follow-up

  6. Change of the mean Visual Analogue Scale (VAS) on pain in the leg and buttock (experienced in the pain-dominant leg) [ Time Frame: Change from the preoperative baseline to the 2 year postoperative assessment ]
    clinical follow-up

  7. Visual Analogue Scale (VAS) on patient's satisfaction with the surgery [ Time Frame: 2 years postoperatively ]
    clinical follow-up

  8. Change of the mean disc height at index level [ Time Frame: Change from the preoperative baseline to the 2 year postoperative assessment ]
    Outcome Measure by CT/MRI and clinical follow-up

  9. Rate of symptomatic adjacent segment disease [ Time Frame: 2 years postoperatively ]
    Outcome Measure by CT/MRI and clinical follow-up



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic of selected spine centers
Criteria

Inclusion Criteria:

  • Symptomatic degenerative disc disease or degenerative spondylolisthesis grade 1 or 2 with chronic low back pain, pain in the leg or buttock, muscle weakness, sensation abnormalities and/or neurogenic claudication
  • Unsuccessful adequate conservative treatment
  • 1- or 2- contiguous level lumbar spinal fusion between L2 and S1 with posterior instrumentation in combination with Transforaminal Lumbar Interbody Fusion (TLIF)
  • Age between 18 - 80 years at the time of surgery
  • Skeletally mature patient
  • Patient understands the conditions of the study and is willing and able to comply with the postoperative scheduled clinical and imaging evaluations and the prescribed rehabilitation
  • Patient signed Informed Consent

Exclusion Criteria:

  • No adequate non-operative care prior to being treated with a lumbar fusion device
  • 3-level fusion or more
  • Fusion not between L2 and S1
  • Previous lumbar spinal surgery, other than discectomy at the level(s) to be operated on
  • Spondylolisthesis acc. to Meyerding grade 3 or higher
  • Transforaminal access to the disc space is obstructed
  • Use of bone grafts other than autologous grafts, demineralized bone matrix without additional growth factors and synthetic bone substitute without additional growth factors. Growth factor enhanced grafts, cement or any other graft material are excluded.
  • Adiposity, severe obesity (BMI > 35 kg/m2)
  • Any contraindication for MRI scan including heart pacemaker, metallic foreign body (metal sliver) in the eye or brain, aneurysm clip in the brain, severe claustrophobia etc.
  • Discitis, spondylodiscitis
  • Acute or chronic infection, previous surgical site infection or severe defect of the osseous structures
  • Open wounds
  • Patient who takes immunosuppressive or long-term steroid use
  • Fever
  • Allergy or intolerance to any device material (e.g. Carbon/PEEK, titanium or tantalum)
  • Foreign body sensitivity
  • Insufficient form fit between the implant and the bone owing to deformation or destruction of the pedicles or of the vertebral body end plates
  • Risk that the intervertebral device can subside into the vertebral bodies
  • Bone tumors in the region of the implant anchoring
  • Severe osteoporosis or similar bone density loss, incl. any metabolic bone disease
  • Cases, in which the progression of degenerative disease is so advanced at the time of implantation that it may substantially decrease the expected useful life of the appliance
  • Systemic or metabolic illnesses (i.e. insulin-dependent diabetes)
  • Patient who is suffering from rheumatological or other inflammatory joint disease
  • Paralysis of lower extremity
  • Generally poor condition of the patient
  • Psychosocial issues; lack of co-operation by the patient
  • Drug abuse or alcoholism
  • Any medical or surgical condition that could preclude the potential success of the implantation
  • Any condition not described in the indications for use
  • Unwillingness or inability of the patient to follow the instructions for postoperative treatment or with the follow-up evaluation schedule
  • Female patient who is pregnant or plans to become pregnant during the course of the study
  • Prisoner
  • Patient who has not signed the Informed Consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02087267


Contacts
Layout table for location contacts
Contact: Christoph Fleege, MD +49 69 6705 1908 Christoph.Fleege@friedrichsheim.de

Locations
Layout table for location information
Germany
Universitätsklinikum SH Klinik für Neurochirurgie Recruiting
Kiel, Schleswig-Holstein, Germany, 24105
Contact: Michael Synowitz, MD    +49 431 500 ext 23600    Michael.Synowitz@uksh.de   
Contact: Senol Jadik, MD    +49 431 500 ext 23600    senol.jadik@uksh.de   
Klinikum Darmstadt, Klinik für Neurochirurgie Active, not recruiting
Darmstadt, Germany, 64283
Orthopädische Universitätsklinik Friedrichsheim gGmbH Recruiting
Frankfurt am Main, Germany, 60528
Contact: Michael Rauschmann, Prof., MD    +49 69 6705-228    m.rauschmann@friedrichsheim.de   
Principal Investigator: Michael Rauschmann, Prof., MD         
Sub-Investigator: Christoph Fleege, MD         
Städtisches Klinikum Görlitz gGmbH, Klinik für Neurochirurgie Recruiting
Görlitz, Germany, 02828
Contact: Marcus Eif, MD    +493581371560    neurochirurgie@klinikum-goerlitz.de   
Principal Investigator: Holger Schenke, MD         
DIAKOVERE Annastift - Orthopädische Klinik der MHH Recruiting
Hanover, Germany, 30625
Contact: Henning Windhagen, Prof.    +49 511 5354 0    henning.windhagen@diakovere.de   
Contact: Dorothea Daentzer, Prof.    +49 511 5354 0    dorothea.daentzer@diakovere.de   
Katholisches Klinikum, Brüderhaus Koblenz Active, not recruiting
Koblenz, Germany, 56073
Switzerland
Kantonsspital St. Gallen Klinik für Orthopädische Chirurgie und Traumatologie des Bewegungsapparates Recruiting
St. Gallen, Switzerland, 9007
Contact: Thomas Forster, MD    +41 71 494 13 96    thomas.forster@kssg.ch   
Principal Investigator: Thomas Forster, MD         
Sub-Investigator: Fabrice A Külling, MD         
Sponsors and Collaborators
Sitona AG
Investigators
Layout table for investigator information
Principal Investigator: Christoph Fleege, MD Orthopädische Universitätsklinik Friedrichsheim

Layout table for additonal information
Responsible Party: Sitona AG
ClinicalTrials.gov Identifier: NCT02087267     History of Changes
Other Study ID Numbers: SITONA_01/2014
First Posted: March 14, 2014    Key Record Dates
Last Update Posted: May 1, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: will be decided in due time

Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylolisthesis
Intervertebral Disc Degeneration
Spondylolysis
Spondylosis
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases